Picard Medical, Inc. (PMI)
| Market Cap | 32.48M |
| Revenue (ttm) | 4.94M |
| Net Income (ttm) | -27.00M |
| Shares Out | 75.18M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,239,491 |
| Open | 0.702 |
| Previous Close | 0.690 |
| Day's Range | 0.430 - 0.706 |
| 52-Week Range | 0.432 - 13.680 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 25, 2026 |
About PMI
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard ... [Read more]
Financial Performance
In 2025, Picard Medical's revenue was $4.94 million, an increase of 12.50% compared to the previous year's $4.39 million. Losses were -$27.00 million, 13.8% more than in 2024.
Financial StatementsNews
Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto
TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the wo...
Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure –
Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
Arizona industry event will highlight patient experience, advanced heart failure care, and the real-world impact of life-sustaining therapies Arizona industry event will highlight patient experience, ...
PICARD MEDICAL DEADLINE APRIL 3rd: Bragar Eagel & Squire, P.C. Urges Picard Medical, Inc. (NYSE:PMI) Investors to Contact the Firm Before April 3rd Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options
Picard Medical Earnings Call Transcript: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 sales expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, positioning the therapy as the new standard of care for adult RRP.
Bragar Eagel & Squire, P.C. Urges Picard Medical, Inc. (NYSE:PMI) Investors to Contact the Firm Before April 3rd Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options
Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs Segment showcases SynCardia Total Artificial Heart supportin...
Shareholders who lost money in shares of Picard Medical, Inc. (NYSE: PMI) should contact Wolf Haldenstein immediately
Lead Plaintiff Deadline is April 3, 2026 NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Picard Medical, ...
Picard Medical/ SynCardia to Present at European Mechanical Circulatory Support Summit and International Course on Mechanical Circulatory Support and New Technologies in Heart Failure
TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Picard Medical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options If you purchased or ...
Picard / SynCardia Featured on the Cruxx of MedTech Podcast
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
SynCardia and Hydrix Enter into Development Collaboration to Advance the Emperor, SynCardia's Next Generation Total Artificial Heart
TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
Picard Medical to Begin Rollout of FDA-Cleared Accessory for its SynCardia Total Artificial Heart
TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world's first total artif...
Picard Medical Announces Up to $50 Million Senior Secured Debt Financing
TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell
Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company's transition to the public markets and continued advancement of their Total Artificial Heart technology Picard Medical, Inc. / SynC...
Picard Celebrates Patient Living a World-Record of Over Eight Years with the SynCardia Total Artificial Heart
-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ev...
Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany
TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025
TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart
Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology Significant milestone reached in advancing...
Picard Reports Third Quarter 2025 Financial Results
– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), ...
Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City
TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artifi...
Picard Issues Statement on Intraday Stock Price
TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Can...
Picard Advances Patent Protection for Fully Implantable Artificial Heart Technology
- Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), par...
Picard Medical Reports Second Quarter 2025 Financial Results
TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Ca...
Picard Medical Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Picard Medical, via SynCardia, leads the total artificial heart market with the only FDA-approved device, strong clinical outcomes, and a focus on US and international expansion. Innovation efforts target a fully implantable heart by 2029, with ongoing label expansion and robust patient support.